A real-world comparison of two androgen receptor pathway inhibitors (ARPIs) for advanced prostate cancer showed a significant difference in overall survival (OS).
2d
Should Johnson & Johnson’s Expanding Oncology Portfolio Alter the Risk Calculus for JNJ Investors?
Johnson & Johnson recently reported real-world data showing that ERLEADA® without docetaxel was associated with a ...
A real-world study found Erleada reduced the risk of death compared with Nubeqa in patients with metastatic ...
Akeega, an oral dual mechanism therapy pairing niraparib with abiraterone, has won a positive committee opinion in Europe for ...
A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to ...
A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to ...
Prostate Cancer Straight Talk led by Jersey City Library Executive Director Terry Hill, boost early screening and support ...
An interim analysis of the prospective BIOPSTAGE trial determined optimal PET thresholds for SUVmax and SUVratio that ...
MCS-8 is developed using Jyong Biotech’s core patented pharmaceutical composition technology, which Company believes significantly enhances bioavailability and improves physiological efficacy, ...
PRESS RELEASEAB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE ...
This clinical overview details the latest evidence-based strategies for diagnosing and treating symptoms of benign prostatic hyperplasia in men.
"There remains an urgent need for novel therapies for patients with BRCA2-mutated mCSPC, who face significantly faster disease progression and often shorter survival compared to those without the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results